Abstract:Background: Psoriasis is an inflammatory skin disease associated with multiple comorbidities and substantially diminishes patients' quality of life. The gut microbiome has become a hot topic in psoriasis as it has been shown to affect both allergy and autoimmunity diseases in recent studies. Our objective was to identify differences in the fecal microbial composition of patients with psoriasis compared with healthy individuals to unravel the microbiota profiling in this autoimmune disease. Results: We collected fecal samples from 30 psoriasis patients and 30 healthy controls, sequenced them by 16S rRNA high-throughput sequencing, and identified the gut microbial composition using bioinformatic analyses including Quantitative Insights into Microbial Ecology (QIIME) and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). Our results showed that different relative abundance of certain bacterial taxa between psoriasis patients and healthy individuals, including Faecalibacterium and Megamonas, were increased in patients with psoriasis. It's also implicated that many cytokines act as main effect molecules in the pathology of psoriasis. We selected the inflammation-related indicators that were abnormal in psoriasis patients and found the microbiome variations were associated with the level of them, especially interleukin-2 receptor showed a positive relationship with Phascolarctobacterium and a negative relationship with the Dialister. The relative abundance of Phascolarctobacterium and Dialister can be regard as predictors of psoriasis activity. The correlation analysis based on microbiota and Inflammation-related indicators showed that microbiota dysbiosis might induce an abnormal immune response in psoriasis. Conclusions: We concluded that the gut microbiome composition in psoriasis patients has been altered markedly and provides evidence to understand the relationship between gut microbiota and psoriasis. More mechanistic experiments are needed to determine whether the differences observed in gut microbiota are the cause or consequences of psoriasis and whether the relationship between gut microbiota and cytokines was involved.

Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response

Gut and Cutaneous Microbiome Featuring Abundance of<i> Lactobacillus</i><i> reuteri</i> Protected Against Psoriasis-Like Inflammation in Mice

Gut and Cutaneous Microbiome Featuring Abundance of Lactobacillus reuteri Protected Against Psoriasis-Like Inflammation in Mice

The Role of Gut Microbiome in Psoriasis: Oral Administration of Staphylococcus aureus and Streptococcus danieliae Exacerbates Skin Inflammation of Imiquimod-Induced Psoriasis-Like Dermatitis

IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function

Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism

Alteration of the Cutaneous Microbiome in Psoriasis and Potential Role in Th17 Polarization.

Immune Portrayal of a New Therapy Targeting Microbiota in an Animal Model of Psoriasis

Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice

Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model

The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics

Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients

Abnormal composition of microbiota in the gut and skin of imiquimod-treated mice

Immunity to commensal skin fungi promotes psoriasiform skin inflammation

Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development

Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies

Intestinal Inflammation Breaks Established Immune Tolerance to a Skin Commensal

Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions

Toll-like Receptor 7/8 Agonists Stimulate Plasmacytoid Dendritic Cells to Initiate TH17-deviated Acute Contact Dermatitis in Human Subjects.

489 TLR7/8 Agonists Stimulate Plasmacytoid Dendritic Cells to Initiate a Th17-deviated Acute Contact Dermatitis in Humans

Study of gut microbiome alterations in plaque psoriasis patients compared to healthy individuals